• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Scharen-Guivel Hilda Frederique converted options into 1,196 shares, increasing direct ownership by 34% to 4,729 units (SEC Form 4)

    12/10/24 9:00:10 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Scharen-Guivel Hilda Frederique

    (Last) (First) (Middle)
    C/O IRADIMED CORPORATION
    1025 WILLA SPRINGS DR.

    (Street)
    WINTER SPRINGS FL 32708

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IRADIMED CORP [ IRMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/07/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/07/2024 M 1,196 A (1) 4,729 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 12/07/2024 M 1,196 (2) (2) Common Stock 1,196 $0 1,197 D
    Explanation of Responses:
    1. Restricted stock units convert into common stock on a one-for-one basis.
    2. On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
    /s/ Hilda F. Scharen-Guivel 12/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

      WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

      5/29/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      11/14/24 3:35:27 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/13/24 4:25:25 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/12/24 12:03:30 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/7/25 4:10:04 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Hawkins James B converted options into 1,196 shares, increasing direct ownership by 4% to 33,545 units (SEC Form 4)

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/4/25 4:45:06 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 100% to 8,767 units (SEC Form 4)

      4 - IRADIMED CORP (0001325618) (Issuer)

      4/4/25 4:45:05 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

      WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

      10/6/22 4:05:00 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

      Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

      6/1/22 9:35:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Financials

    Live finance-specific insights

    See more
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

      4/28/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IRMD
    SEC Filings

    See more
    • Lake Street initiated coverage on iRadimed with a new price target

      Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

      4/12/23 9:17:10 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • iRadimed Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IRADIMED CORP (0001325618) (Filer)

      5/29/25 4:15:13 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by iRadimed Corporation

      10-Q - IRADIMED CORP (0001325618) (Filer)

      5/5/25 4:30:33 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRADIMED CORP (0001325618) (Filer)

      5/5/25 7:00:17 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care